Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Hens that lay human proteins in eggs offer cost-effective method of producing new drugs

Chickens that are genetically modified to produce human proteins in their eggs can offer a cost-effective method of producing certain types of drugs, research suggests.

28 Jan 2019

Insilico Medicine to present latest advances in aging biomarker development at Longevity Leaders Conference

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in human aging biomarker development at the Longevity Leaders Conference in London, 4 of February.

25 Jan 2019

Insilico to present latest findings in AI for Drug Discovery at 3rd Annual SABPA FTD Forum

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the 3rd Annual SABPA FTD Forum in San Diego, California, 2 of February.

23 Jan 2019

Unique data combination helps FinnGen researchers to fund links between genetic factors and health

The FinnGen study, launched in autumn 2017, is a broad academic-industrial collaboration between the Finnish biobanks and their respective Universities, University Hospitals, the Institute of Health and Welfare, the Finnish Red Cross Blood Service and now nine international pharmaceutical companies

23 Jan 2019

Yeast model may pave way for development of novel therapies for metabolic disorders

There are hundreds of metabolic disorders -- including phenylketonuria, tyrosinemia, maple syrup urine disease and homocystinuria.

17 Jan 2019

Researchers find new class of blood pressure-regulating peptides in vampire bat venom

Vampire bats could hold the key to new treatments for a range of serious medical problems, but researchers have hit a snag accessing the specimens needed to advance their work.

17 Jan 2019

Smoking significantly increases your biological age, study shows

Insilico Medicine, one of the leaders in artificial intelligence for drug discovery, biomarker development, digital medicine, and aging research, announced the publication of a new collaborative research paper titled "Blood Biochemistry Analysis to Detect Smoking Status and Quantify Accelerated Aging in Smokers" in Scientific Reports.

17 Jan 2019

How Patch Clamp Technology Can Benefit Ion Channel Research

Learn how patch clamp technology meets high-throughput to benefit ion channel research in this interview with Tim and James, Nanion.

From Nanion Technologies 16 Jan 2019

Hamilton Storage launches LabElite DeCapper SL to expand LabElite product family

Hamilton Storage introduces a new member of the LabElite product family with the launch of the LabElite DeCapper SL.

16 Jan 2019

TGF-beta signaling pathway in uterine cells protects against cancer

Two new mouse models of uterine cancer shed light on how this disease - the most common gynecological cancer in the U.S. - happens.

16 Jan 2019

University of Nebraska to develop new drugs that prevent and counteract effects of radiation exposure

The U.S. Department of Defense has turned to the University of Nebraska to jumpstart the development of drug therapies to protect military service members from the effects of radiation exposure.

16 Jan 2019

New evidence shows how fever alters immune cells

Fever is known to help power up our immune cells, and scientists in Shanghai have new evidence explaining how.

16 Jan 2019

Study points to potential new biomarker and drug target for amyotrophic lateral sclerosis

Research led by stem cell scientists at Harvard University points to a potential new biomarker and drug target for amyotrophic lateral sclerosis, a neurological disease that is extremely difficult to diagnose and treat.

16 Jan 2019

Training Students to use Imaging Techniques: NMR and EPR

In this interview, Judy MacInnis from Cape Breton university, explains the importance of giving students hands-on EPR experience during in their studies.

From Bruker BioSpin Group 15 Jan 2019

Conducting ChIP-Seq with Low Cell Numbers

An interview with Dr. Kathyrn Cunningham at SfN 2018, providing advice on carrying out Chromatin Immunoprecipitation Sequencing (ChIP-seq) with low cell numbers.

From Active Motif 14 Jan 2019

Aptamer Group and AstraZeneca to develop new drug delivery vehicles

Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney.

From AstraZeneca 10 Jan 2019

Drug development options diversified with new manganese catalyst

A University of Illinois team of researchers led by chemistry professor M. Christina White has developed a new manganese-based catalyst that can change the structure of druglike molecules to make new drugs, advancing the pace and efficiency of drug development.

9 Jan 2019

TARA Biosystems and Insilico Medicine collaborate to discover novel therapies for cardiac disease

TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and risk assessment applications and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop novel therapies for cardiac disease and diseases associated with cardiac muscle aging.

9 Jan 2019

CytoReason enters into drug discovery collaboration agreement with Pfizer

CytoReason, a leader in machine learning for drug discovery and development, announced today that it has entered into a collaboration agreement with Pfizer Inc. that will leverage CytoReason's cell-centered models of the immune system.

8 Jan 2019

Insilico Medicine and TARA Biosystems collaborate to develop novel therapies for cardiac diseases

Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases and TARA Biosystems, Inc. a company offering "heart-on-a-chip" tissue models for drug discovery and risk assessment applications, announced today the launch of a collaboration to discover and develop novel therapies for cardiac disease and diseases associated with cardiac muscle aging.

8 Jan 2019

Drug Discovery News and Research

Further Reading

Hens that lay human proteins in eggs offer cost-effective method of producing new drugs

Insilico Medicine to present latest advances in aging biomarker development at Longevity Leaders Conference

Insilico to present latest findings in AI for Drug Discovery at 3rd Annual SABPA FTD Forum

Unique data combination helps FinnGen researchers to fund links between genetic factors and health

Yeast model may pave way for development of novel therapies for metabolic disorders

Researchers find new class of blood pressure-regulating peptides in vampire bat venom

Smoking significantly increases your biological age, study shows

How Patch Clamp Technology Can Benefit Ion Channel Research

Hamilton Storage launches LabElite DeCapper SL to expand LabElite product family

TGF-beta signaling pathway in uterine cells protects against cancer

University of Nebraska to develop new drugs that prevent and counteract effects of radiation exposure

New evidence shows how fever alters immune cells

Study points to potential new biomarker and drug target for amyotrophic lateral sclerosis

Training Students to use Imaging Techniques: NMR and EPR

Conducting ChIP-Seq with Low Cell Numbers

Aptamer Group and AstraZeneca to develop new drug delivery vehicles

Drug development options diversified with new manganese catalyst

TARA Biosystems and Insilico Medicine collaborate to discover novel therapies for cardiac disease

CytoReason enters into drug discovery collaboration agreement with Pfizer

Insilico Medicine and TARA Biosystems collaborate to develop novel therapies for cardiac diseases

Enabling smarter drug development with radiolabeled chemistry and metabolism expertise eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo